Clinical oncological applications of positron emission tomography (PET) using fluorine-18-fluoro-2-deoxy-D-glucose;Applicazioni della tomografia ad emissione di positroni (PET) con [fluoro-18]-fluoro-2-desossi-D-glucosio nella pratica clinica oncologica

Radiologia Medica

Volumn 103, Issue 4, 2002, Pages 293-318

  Giorgetti, Assuero ^a   Volterrani, Duccio ^b   Mariani, Giuliano ^a,b  

^a CNR   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Diagnosis; Evaluation of the efficacy of treatment; Metabolic functional tracers; Oncological applications; Positron Emission Tomography; Staging

Indexed keywords

CARBON 11; FLUORODEOXYGLUCOSE F 18; NITROGEN 13; OXYGEN 15; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BRAIN TUMOR; BREAST CANCER; CANCER; CANCER DIAGNOSIS; CANCER GRADING; CELL PROLIFERATION; COLON CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LYMPHOMA; MELANOMA; MUSCLE CANCER; OVARY CANCER; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; TREATMENT PLANNING;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM STAGING; NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036089467     PISSN: 00338362     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (146)

1. The use of radioactive oxygen-15 in the determination of oxygen content in malignant neoplasms
2. Positron scanning
3. Positron scanner for locating brain tumors
4. Optimal scan time for fluorine-18 fluoro-deoxyglucose positron emission tomography in breast cancer
5. Delayed FDG PET scan for differentiation between malignant and benign lesions in the pancreas
6. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic tracer for rapid tumor dection
7. Standardized uptake values of normal tissues at PET with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose: Variations with body weight and a method for correction
8. 18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations
9. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data
10. A tabulated summary of the FDG PET literature
11. FDG-PET for clinical use. Results of the 3rd German interdisciplinary consensus conference, "onko-Pet III", 21 July and 19 September 2000
12. 18F) fluorodeoxyglucose and positron emission tomography
13. Optimal cut-off levels of F-18 fluorodeoxyglucose uptake in the differentiated of low grade from high grade brain tumors with PET
14. Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors
15. Positron emission tomography in patients with glioma. A predictor of prognosis
16. Neuroimaging of juvenile pilocytic astrocytomas: An enigma
17. 11C] methionine
18. Delineation of gliomas with magnetic resonance imaging using Gd-DTPA in comparison with computed tomography and positron emission tomography
19. 11C-methionine and survival in patients with low-grade gliomas
20. 11C]thymidine positron emission tomography in tumoral and nontumoral cerebral lesions
21. PET scanning and the human immunodeficiency virus-positive patient
22. Functional MR and PET imaging of rolandic and visual cortices for neurosurgical planning
23. 18F]fluorodeoxyglucose
24. Solitary pulmonary nodules: Detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose
25. Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning
26. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management
27. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis
28. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging
29. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET
30. Characterization of pulmonary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose positron emission tomography
31. Likelihood of malignancy in a solitary pulmonary nodule: Comparison of Bayesian analysis and results of FDG-PET scan
32. Radiologic evaluation in lung cancer: Diagnosis and staging
33. Thoracic FDG PET: State of the art
34. Prospective investigation of positron emission tomography in lung nodules
35. Analytical decision model for the cost-effective management of solitary pulmonary nodules
36. 18F]fluorodeoxyglucose in the evaluation of pulmonary nodules
37. Strategy and cost in investigating solitary pulmonary nodules
38. Nuclear medicine procedures in lung cancer
39. Solitary pulmonary nodules: Part II. Evaluation of the indeterminate nodule
40. 18F]fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer
41. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: A decision analysis based on cost reimbursement in Germany
42. Preliminary findings of a prospective study of FDG-PET in patients with possible lung cancer
43. FDG-PET as a "metabolic biopsy" tool in thoracic lesions with indeterminate biopsy
44. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis
45. 18F-fluoro-2-deoxy-D-glucose in respiratory oncology
46. Accuracy of F-18 fluorodeoxyglucose positron emission tomography for the evaluation of malignancy in patients presenting with new lung abnormalities: A retrospective review
47. Patterns of abnormal FDG uptake by various histological types of non-small cell lung cancer at initial staging by PET
48. Positron emission tomography (PET) of non-small cell lung cancer
49. Imaging of lung cancer with CT, MRT and PET
50. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging
51. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer
52. 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification
53. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: Powerful correlation with survival and high impact on treatment
54. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose
55. Breast imaging with fluorine-18-FDG PET: Quantitative image analysis
56. The potential of F-18-FDG PET in breast cancer. Detection of primary lesions, axillary lymph node metastases, or distant metastases
57. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations
58. 18-FDG imaging in breast cancer
59. Current status of PET in breast cancer imaging, staging, and therapy
60. 18F-FDG PET on staging and managing patients with breast cancer: The referring physician's perspective
61. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: Comparison with the standard staging procedures
62. Tumor related prognostic factors for breast cancer
63. Significance of axillary lymph node metastasis in primary breast cancer
64. Axillary dissection in breast cancer: When, why, how much, and for how long? Another operation soon to be extinct?
65. Axillary lymph nodes and breast cancer
66. Addressing the axilla in breast cancer
67. Radioguided sentinel lymph node biopsy in breast cancer surgery
68. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma
69. 18F-fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer
70. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer
71. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer
72. 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: A comparative study
73. 18F-fluorodeoxyglucose positron emission tomography in the early assessment of response to chemotherapy in metastatic breast cancer patients
74. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma
75. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity
76. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: Correlation with CT
77. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma
78. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging
79. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography
80. 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
81. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma comparison with CT
82. 2-(Fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial
83. Whole body positron emission tomography in the treatment of Hodgkin disease
84. 18F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
85. 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
86. 18F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma
87. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment
88. PET scanning in head and neck oncology: A review
89. 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer
90. 18FDG-PET for the assessment of primary head and neck tumors: Clinical, computed tomography, and histopathological correlation in 38 patients
91. Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors
92. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer
93. Clinical utility of FDG-PET in detecting head and neck tumors. A comparison of diagnostic methods and modalities
94. 18F-FDG PET: A comparison with conventional methods
95. Positron emission tomography in the evaluation of stage III and IV head and neck cancer
96. 18F-fluoro-2-deoxy-D-glucose positron emission tomography
97. Surveillance for recurrent head and neck cancer using positron emission tomography
98. FDG PET to evaluate combined intraarterial chemotherapy and radiotherapy of head and neck neoplasms
99. The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the NO neck
100. FDG-PET and CT in evaluation of chemotherapy in advanced head and neck cancer
101. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer
102. F-18-fluoro-deoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer
103. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: Results of a multicentre study
104. 18F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy
105. 131 I whole body scan
106. Flourine-18 flourodeoxy glucose positron emisson tomography and iodine-131 whole body scintigraphy in the follow-up of differentiated thyroid cancer
107. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicentre study
108. Staging of colorectal cancer
109. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum
110. F-18 FDG PET for suspected or confirmed regional recurrence of colon cancer. A prospective study of impact and outcome
111. Whole-body FDG-PET in patients with recurrent colorectal carcinoma. A comparative study with CT
112. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer
113. 18F-FDG PET on managing patients with colorectal cancer: The referring physician's perspective
114. Decision analysis for the costeffective management of recurrent colorectal cancer
115. Positron emission tomography and colorectal cancer
116. Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal cancer and liver metastases: A prospective study
117. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study
118. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas
119. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: A report of 106 cases
120. Diagnosis of pancreatic carcinoma: Role of FDG PET
121. FDG-PET in the prediction of survival of patients with cancer of the pancreas: A pilot study
122. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies
123. 18F-fluorodeoxyglucose positron emission tomography
124. Improvement in staging of esophageal cancer with the addition of positron emission tomography
125. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma
126. Positron emission tomography scanning in malignant melanoma
127. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma
128. Diagnosis and monitoring of urological tumors using positron emission tomography
129. 18F-fluoro-D-glucose: Pilot animal and human studies
130. FDG PET characterization of renal masses: Preliminary experience
131. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer
132. PET imaging of prostate cancer using carbon-11-choline
133. 18F]deoxyglucose (2-[18F]FDG)
134. 18F-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma
135. FDG PET for detection and therapy control of metastatic germ cell tumor
136. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer
137. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: Correlation with second-look laparotomy
138. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer
139. Fluorodeoxyglucose PET in the initial staging of germ cell tumours
140. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma
141. Detection of unknown occult primary tumors using positron emission tomography
142. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumour (UPT)
143. 18F-FDG whole body positron emission tomography (PET) in the detection of unknown primary tumors
144. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation